XCell’s Retinal Pigmented Epithelium (RPE) cells are derived from a cGMP-compatible human iPSC line, NCL2-GFP. These RPE cells are manufactured using our cGMP-compatible process. These high-quality RPE cells can be maintained in XCell’s Retinal Pigment Epithelium Medium (XR-RPE-001-PACK) to reach maturation, demonstrated by the expression of key RPE markers such as MITF, Bestrophin, and RPE65. Our RPE cells are supplied in a cryopreserved vial and can be passaged, expanded, and banked (at early stage of maturation) for future utilization.
These RPE cells are ideal source material to study the onset and progression of age-related macular degeneration and other retinal diseases associated with degeneration of the retinal pigmented epithelium layer of the eye. Those cells can be used alone or in co-culture with other retinal cell types to build physiologically relevant in vitro cellular models for drug screening and toxicology studies. The GFP expressing RPE cells can also be delivered alone or together with other neuroretinal cell types into animal models to develop cell replacement therapies for these devastating diseases.